GLP-1 analogue-induced weight loss does not improve obesity-induced AT dysfunction
- Design
- Randomized trial · 30 participants · Biomarker outcome
- Match to healthy normal-weight adults aged 55–75
- Different populationINDIRECT: all participants had type 2 diabetes; the abstract gives no age, sex or BMI data.
- Could weight loss explain it?
- UnlikelyThe comparator was weight loss by calorie restriction, and the adipose tissue inflammatory rise seen with liraglutide did not occur with diet; the abstract does not say weight loss was matched between arms or adjusted for; no cached full text.
- Study tier
- Study tier 3LOW: small randomised trial (30 participants, 22 vs 8) with adipose tissue biomarker outcomes over 4 months; abstract only.
- Assessment
- Version 2 · Two reviewers differed; settled by a recorded ruling · Oct 19, 2026
Study facts come from the paper. Population match, weight-loss explanation and study tier are our judgments, made against the reference group of healthy normal-weight adults aged 55–75.
This small randomised trial in 30 people with type 2 diabetes compared 4 months of liraglutide (22 people) with calorie restriction (8 people), using repeated biopsies of fat under the skin. Liraglutide led to weight loss (-3.12±1.72 kg) and lowered fasting glucose more than diet, but it raised inflammatory and scarring-related gene activity in the fat tissue (TNFA, P=0.0005), which the diet group did not show. These are tissue markers, not clinical outcomes, and only the abstract was available.
01Findings
What the study reported
- Drugs
- Liraglutide
- Comparator
- calorie restriction based on dietetic counselling
- Treatment duration
- 4 months
- Primary outcome
- Subcutaneous adipose tissue inflammatory and fibrotic responses on repeated biopsies, compared with calorie-restriction weight loss
- Effect
- With liraglutide, weight fell 3.12±1.72 kg (P=0.007) and visceral fat fell, but adipose tissue TNFA expression (P=0.0005), MCP-1 expression (P=0.027) and serum MCP-1 (P=0.048) rose and TGFB1 and COL1A1 expression increased; in the diet arm CD14 expression showed a lower trend (P=0.09)
- 95% confidence interval
- Not extracted
- P value
- P=0.0005 (adipose tissue TNFA expression with liraglutide); P=0.027 and P=0.048 (MCP-1 expression and serum level)
- Follow-up
- Not stated
- Adverse events
- not reported in abstract
- Limitations
- Small randomised trial with unequal arms (22 vs 8) over 4 months, adipose tissue biopsy markers only, modest weight loss and no blinding stated; only the abstract was available, and whether the changes limit fat storage capacity is unknown.
Who was studied
- Obesity status
- not reported in abstract
- Diabetes status
- type 2 diabetes required
- Cvd status
- not reported in abstract
- Ckd status
- not reported in abstract
- Baseline condition
- type 2 diabetes
- Sample size
- 30
- Inclusion exclusion
- type 2 diabetes; age-matched
Study quality details
- Study design
- Randomized controlled trial
- Sample size
- 30
- Randomization
- yes
- Blinding
- not stated
- Comparator
- calorie restriction based on dietetic counselling
- Follow up duration
- not stated
- Outcome type
- biomarker
- Replication
- not assessed
- Consistency with other evidence
- not assessed
- Population applicability
- INDIRECT
- Statistical precision
- no CI reported; P values only; small, unbalanced arms (22 vs 8)
- Risk of bias
- not assessed
- Funding conflicts
- unclear
- Peer review status
- yes
02Funding
Funding and conflicts
- Funding
- not reported in abstract
- Industry funded
- Unclear
- Manufacturer
- not stated in source
- Sponsor role
- not reported in abstract
- Author conflicts
- not reported in abstract
- Independent replication
- unknown
Funding is shown on every study and never used to score it.
03Claims
Claims this study bears on
- GLP-1 receptor agonist treatment reduces systemic inflammatory markers beyond what can be explained by treatment-associated weight loss.Contradicts
Randomised study in 30 adults with T2D (liraglutide n=22, calorie restriction n=8, 4 months): subcutaneous adipose TNFA and MCP-1 expression and serum MCP-1 increased with liraglutide, while the diet arm showed only a non-significant trend to lower CD14 expression. Weight loss on liraglutide was 3.12 kg, the arms are not stated to be weight-matched, and the abstract reports no CRP or IL-6.
04Source
The source, as retrieved
Abstract
Glucagon-like peptide-1 (GLP-1) analogues aid weight loss that improves obesity-associated adipose tissue (AT) dysfunction. GLP-1 treatment may however also directly influence AT that expresses the GLP-1 receptor (GLP-1R). The present study aimed to assess the impact of GLP-1 analogue treatment on subcutaneous AT (SCAT) inflammatory and fibrotic responses, compared with weight loss by calorie reduction (control). Among the 39 participants with Type 2 diabetes recruited, 30 age-matched participants were randomized to 4 months treatment with Liraglutide (n=22) or calorie restriction based on dietetic counselling (n=8). Assessments included clinical characteristics and repeated subcutaneous abdominal AT biopsies. Liraglutide resulted in weight loss in most participants (-3.12±1.72 kg, P=0.007) and significant reduction in visceral AT (VAT). It was more effective in lowering fasting glucose, in comparison with weight loss by dieting. However, tumour necrosis factor-α (TNFA) AT-expression (P=0.0005), macrophage chemoattractant protein-1 (MCP-1) expression (P=0.027) and its serum levels (P=0.048) increased with Liraglutide, suggestive of an inflammatory response unlike in the diet arm in which a trend of lower cluster of differentiation 14 (CD14) expression (P=0.09) was found. Liraglutide treatment also increased expression of factors involved in extracellular matrix (ECM) deposition, transforming growth factor-β (TGFB) and collagen type 1 alpha 1 chain (COL1A1) (TGFB1: before 0.73±0.09 arbitrary units (AU), after 1.00±0.13 AU, P=0.006; COL1A1: 0.84±0.09 AU compared with 1.49±0.26 AU, P=0.026). Liraglutide thus appears to induce an inflammatory response in AT and influences ECM remodelling. Despite its superior effect on glycaemia, Liraglutide does not improve obesity-associated AT dysfunction in subcutaneous tissue. It is yet unclear whether this limits AT storage capacity for lipids. This may be of importance in patients being re-exposed to positive energy balance such as post GLP-1 discontinuation.